Market Cap 281.06M
Revenue (ttm) 341.92M
Net Income (ttm) 20.95M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 6.13%
Debt to Equity Ratio 0.00
Volume 570,300
Avg Vol 275,218
Day's Range N/A - N/A
Shares Out 46.84M
Stochastic %K 0%
Beta N/A
Analysts Sell
Price Target $10.50

Company Profile

CapsoVision, Inc., a medical technology company, manufactures and markets endoscopic video imaging devices focused on internal imaging of the gastrointestinal system. It offers CapsoCam Plus, a capsule endoscopy system for visualization of the small bowel mucosa in adults and children aged 2 years and above; and CapsoCam Colon for visualization of the colon and detection and measurement of polyps, as well as develops CapsoColon 3D for large intestines (colon). The company also provides CapsoClou...

Industry: Medical Devices
Sector: Healthcare
Phone: 408 624 1488
Fax: 408 370 4795
Address:
18805 Cox Avenue, Suite 250, Saratoga, United States
FeliciaMath
FeliciaMath Jan. 14 at 7:19 PM
bought $CV at 6.01
0 · Reply
REDBEAR
REDBEAR Jan. 13 at 6:41 PM
$CV stocktwits, wtf is this? fix it. i need to read the comments and ask if this is a good buy?
1 · Reply
garygb
garygb Jan. 11 at 3:03 PM
$CV This is having a bad year. Down and forgotten while sitting on the leading edge of ai in medicine. Best longshot I know of. Doubling down and holding tight.
0 · Reply
ZacksResearch
ZacksResearch Jan. 2 at 5:37 PM
$CV is bringing AI into capsule endoscopy — and FDA is the next gate. CapsoVision has submitted an FDA 510(k) to add an AI-assisted reading module to CapsoCam Plus, aiming to boost diagnostic accuracy and streamline clinical reviews. 🧠⚕️ See why this AI upgrade could be a meaningful catalyst 👉 https://www.zacks.com/stock/news/2811389/capsovision-submits-fda-510k-for-ai-assisted-module-in-capsocam-plus?cid=sm-stocktwits-2-2811389-teaser-27207&ADID=SYND_STOCKTWITS_TWEET_2_2811389_TEASER_27207
0 · Reply
ZacksResearch
ZacksResearch Jan. 2 at 4:17 PM
$CV drops 7.7% post-announcement — what’s behind the slide? 🤔 Despite a 205.4% surge over six months, the recent dip coincides with CV's FDA submission for an AI reading feature in its CapsoCam Plus system. This AI-enhancement aims to boost diagnostic accuracy and efficiency but needs clearance first. Full scoop here 👉 https://www.zacks.com/stock/news/2811389/capsovision-submits-fda-510k-for-ai-assisted-module-in-capsocam-plus?cid=sm-stocktwits-2-2811389-body-27182&ADID=SYND_STOCKTWITS_TWEET_2_2811389_BODY_27182
0 · Reply
medguy
medguy Jan. 1 at 12:12 AM
Looking for a bounce $AFJK $TRON $CV $CORT
0 · Reply
Easteregg
Easteregg Dec. 30 at 5:46 PM
$CV Does their technology have any advantage over the competition? Anyone knowledgeable about this company?
0 · Reply
topstockalerts
topstockalerts Dec. 29 at 1:58 PM
Pre Market Top Gainers PT2 $ANL $AFJK $SOPA $CV $BRLS
0 · Reply
topstockalerts
topstockalerts Dec. 22 at 3:01 PM
Top Gainers PT2 $ADEA $EQ.X $LSH $BYSI $CV
0 · Reply
topstockalerts
topstockalerts Dec. 22 at 1:01 PM
Pre Market Top Gainers PT2 $CV $FTCI $NUWE $AAME $VELO
0 · Reply
FeliciaMath
FeliciaMath Jan. 14 at 7:19 PM
bought $CV at 6.01
0 · Reply
REDBEAR
REDBEAR Jan. 13 at 6:41 PM
$CV stocktwits, wtf is this? fix it. i need to read the comments and ask if this is a good buy?
1 · Reply
garygb
garygb Jan. 11 at 3:03 PM
$CV This is having a bad year. Down and forgotten while sitting on the leading edge of ai in medicine. Best longshot I know of. Doubling down and holding tight.
0 · Reply
ZacksResearch
ZacksResearch Jan. 2 at 5:37 PM
$CV is bringing AI into capsule endoscopy — and FDA is the next gate. CapsoVision has submitted an FDA 510(k) to add an AI-assisted reading module to CapsoCam Plus, aiming to boost diagnostic accuracy and streamline clinical reviews. 🧠⚕️ See why this AI upgrade could be a meaningful catalyst 👉 https://www.zacks.com/stock/news/2811389/capsovision-submits-fda-510k-for-ai-assisted-module-in-capsocam-plus?cid=sm-stocktwits-2-2811389-teaser-27207&ADID=SYND_STOCKTWITS_TWEET_2_2811389_TEASER_27207
0 · Reply
ZacksResearch
ZacksResearch Jan. 2 at 4:17 PM
$CV drops 7.7% post-announcement — what’s behind the slide? 🤔 Despite a 205.4% surge over six months, the recent dip coincides with CV's FDA submission for an AI reading feature in its CapsoCam Plus system. This AI-enhancement aims to boost diagnostic accuracy and efficiency but needs clearance first. Full scoop here 👉 https://www.zacks.com/stock/news/2811389/capsovision-submits-fda-510k-for-ai-assisted-module-in-capsocam-plus?cid=sm-stocktwits-2-2811389-body-27182&ADID=SYND_STOCKTWITS_TWEET_2_2811389_BODY_27182
0 · Reply
medguy
medguy Jan. 1 at 12:12 AM
Looking for a bounce $AFJK $TRON $CV $CORT
0 · Reply
Easteregg
Easteregg Dec. 30 at 5:46 PM
$CV Does their technology have any advantage over the competition? Anyone knowledgeable about this company?
0 · Reply
topstockalerts
topstockalerts Dec. 29 at 1:58 PM
Pre Market Top Gainers PT2 $ANL $AFJK $SOPA $CV $BRLS
0 · Reply
topstockalerts
topstockalerts Dec. 22 at 3:01 PM
Top Gainers PT2 $ADEA $EQ.X $LSH $BYSI $CV
0 · Reply
topstockalerts
topstockalerts Dec. 22 at 1:01 PM
Pre Market Top Gainers PT2 $CV $FTCI $NUWE $AAME $VELO
0 · Reply
Brandz141
Brandz141 Dec. 19 at 9:01 PM
$LUNR hold my beer said $CV 😂
0 · Reply
SuperGreenToday
SuperGreenToday Dec. 17 at 3:54 PM
0 · Reply
BioGem
BioGem Dec. 16 at 5:08 AM
$CV Will build a short position in this huge bubble. Not sure if anyone has looked at their strange financials: -Revenue near 3M per Q has basically no growth. -Losses are deeper by the day with bigger cash burn. -Cash is near zero by early 2026. -Lock up period is in a few weeks. -A big offering and dilution is a certainty. -No catalyst for the next 6 months. -Even the pumper analysts have a price target of $5-6.
0 · Reply
Grubstake
Grubstake Dec. 15 at 1:19 PM
0 · Reply
Tungst10
Tungst10 Dec. 13 at 8:32 PM
🌙 PRE-MARKET WATCHLIST 🌙 $CV 🚀 watching for break over 19.00 ✂️ Cut (10% SL): under 17.10 🎯 Take-profit levels: 19.50 / 20.00 / 20
0 · Reply
ATerragna
ATerragna Dec. 12 at 5:52 PM
$CV 600 means apply resistance to prevent the price from increasing.
0 · Reply
ATerragna
ATerragna Dec. 12 at 4:56 PM
0 · Reply
ATerragna
ATerragna Dec. 12 at 4:50 PM
$CV needs $OCG volume to continue this bullish trend since $4
0 · Reply
ATerragna
ATerragna Dec. 12 at 4:21 PM
$RYM profits to $CV . Same entry price. PT 24+
0 · Reply
Grubstake
Grubstake Dec. 12 at 2:12 PM
0 · Reply
swingtogain
swingtogain Dec. 12 at 1:12 PM
$CV this will run
0 · Reply
ATerragna
ATerragna Dec. 12 at 11:58 AM
$CV CAPSOVISION (NASDAQ: CV) STOCK ROCKETS AFTER-HOURS: PRICE ACTION, Q3 EARNINGS AND 2026 OUTLOOK https://ts2.tech/en/capsovision-nasdaq-cv-stock-rockets-after-hours-price-action-q3-earnings-and-2026-outlook/
1 · Reply